Switzerland-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has closed a private US$152m Series B financing and initiation of HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT).
The Series B financing, co-led...
US-based CareTrust REIT has revealed the acquisition of a portfolio of 16 care homes across England and Scotland for an initial investment of approximately US$226m, inclusive of transaction costs. It says the portfolio is operated under a long-term lease to an experienced management team with a track record of successful care home operations.
“This was a complicated deal to get across the line,” said James Callister, CareTrust’s CIO. “It further expands our rapidly growing UK footprint and reflects how we're sourcing and executing quality opportunities in the region.”
The company also...